Get started
Author

Andreas Schröder

Observed names: A J Schröder, A. J. Schröder, A. Schröder, Andreas J Schroder, Andreas J Schröder, Andreas J. Schröder, Andreas Johannes Schröder, Andreas Schroeder, Andreas Schröder, Schröder, Andreas
Observed institutions: Goethe University Frankfurt, Merck KGaA, Darmstadt (Germany), Heidelberg University, Columbia University Irving Medical Center, CureVac (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Columbia University
ORCID: 0000-0002-3568-1358
Observed ORCID: 0000-0002-3568-1358
OpenAlex ID: A5035675757
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
2013 · Charles Butts, Mark A Socinski, et al. · The Lancet Oncology · 539
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
2019 · Alexandros Papachristofilou, Madeleine M. Hipp, et al. · Journal for ImmunoTherapy of Cancer · 228
PDF
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
2019 · Martin Sebastian, Andreas Schröder, et al. · Cancer Immunology Immunotherapy · 209
IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching
2009 · Masaki Kashiwada, Deborah M. Levy, et al. · Proceedings of the National Academy of Sciences · 183
Autoimmunity and Inflammation Due to a Gain-of-Function Mutation in Phospholipase Cγ2 that Specifically Increases External Ca2+ Entry
2005 · Philipp Yu, Rainer Constien, et al. · Immunity · 177
PDF
Cutting Edge: STAT6 Serves as a Positive and Negative Regulator of Gene Expression in IL-4-Stimulated B Lymphocytes
2002 · Andreas J Schroder, Paul Pavlidis, et al. · The Journal of Immunology · 95
PDF
Cutting Edge: IL-4 Induces Suppressor of Cytokine Signaling-3 Expression in B Cells by a Mechanism Dependent on Activation of p38 MAPK
2005 · Stephen Canfield, Youngnam Lee, et al. · The Journal of Immunology · 66
PDF
The Transcriptional Co-activator p/CIP (NCoA-3) Is Up-regulated by STAT6 and Serves as a Positive Regulator of Transcriptional Activation by STAT6
2004 · Akinori Arimura, Maartje van Peer, et al. · Journal of Biological Chemistry · 60
PDF
Phosphatidylinositol 3-Kinase Functions as a Ras Effector in the Signaling Cascade That Regulates Dephosphorylation of the Actin-Remodeling Protein Cofilin after Costimulation of Untransformed Human T Lymphocytes
2006 · Guido H Wabnitz, Gabriele Nebl, et al. · The Journal of Immunology · 56
Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
2017 · A. Stenzl, S. Feyerabend, et al. · Annals of Oncology · 55
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
2021 · Michael R. Shafique, Terrence L. Fisher, et al. · Clinical Cancer Research · 32
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
2025 · Jean Bourhis, Lisa F. Licitra, et al. · Journal of Clinical Oncology · 24
PDF
Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study
2014 · Eva Rossmann, Anders Österborg, et al. · Human Vaccines & Immunotherapeutics · 24
Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
2016 · Henoch S. Hong, Sven D. Koch, et al. · OncoImmunology · 22
PDF
Conversion of p56lck to p60lck in human peripheral blood T lymphocytes is dependent on co- stimulation through accessory receptors: involvement of phospholipase C, protein kinase C and MAP-kinases in vivo
2000 · Andreas Johannes Schröder, Petra Quehl, et al. · European Journal of Immunology · 22
PDF
Effects of Proinflammatory Cytokines on Cultivated Primary Human Hepatocytes
1995 · Andreas J. Schröder, Roman A. Blaheta, et al. · Transplantation · 20
Up-regulation of the phosphoinositide 3-kinase pathway in human lamina propria T lymphocytes
2008 · J Braunstein, F Autschbach, et al. · Clinical & Experimental Immunology · 12
PDF
[Isolation and separation of human adult hepatocytes from resected liver: cellular yield and purity using different methods].
1994 · A J Schröder, R A Blaheta, et al. · PubMed · 9
Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review
2025 · Paolo Bossi, Naomi Kiyota, et al. · Oral Oncology · 6
Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
2019 · Michael Rahman Shafique, Terrence Lee Fisher, et al. · Journal of Clinical Oncology · 3
Randomized Phase II Study of BLP25 Liposome Vaccine (L-BLP25) in Patients with Multiple Myeloma
2011 · Eva Rossmann, Anders Österborg, et al. · Blood · 3
Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
2023 · Yulia Vugmeyster, Abhigyan Ravula, et al. · Journal of Clinical Oncology · 1
PDF
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
2020 · Michael Rahman Shafique, Terrence Lee Fisher, et al. · Journal of Clinical Oncology · 1
P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC
2017 · Alexandros Papachristofilou, Martin Sebastian, et al. · Journal of Thoracic Oncology · 1
Abstract B072: Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with disease control after first-line chemotherapy or during therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Updated clinical results and immune responses
2016 · M. M. Hipp, M. Sebastian, et al. · Cancer Immunology Research · 1
Works count: 31
Citation count: 1,848
H-index: 16
I10-index: 17
Year
Topic
Type